October 15-16, Alliance representatives are attending the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in Marina del Ray, CA.   November 1-4, we’ll be in Boca Raton, FL for CNS Summit.   We look forward to hearing from knowledgeable speakers, and meeting with industry associates to discuss our capabilities and extensive…

October 10-11, Alliance representatives are attending the 12th Annual Pain & Migraine Therapeutics Summit in San Francisco, CA.   December 11-13, we’ll be in Boston for the inaugural World Migraine Forum.   We look forward to hearing from knowledgeable speakers and meeting with industry associates to discuss our capabilities and extensive experience with pain and…

Alliance representatives are attending the following Outsourcing conferences: Outsourcing in Clinical Trials Southern California 2018 September 26–27 in La Jolla, CA Outsourcing in Clinical Trials Pacific Northwest 2018 October 16-17 in Vancouver, BC Outsourcing in Clinical Trials New England 2018 November 6-7 in Boston, MA We look forward to learning about sponsors’ outsourcing challenges, and…

July 22-26, Alliance representatives are attending the Alzheimer’s Association International Conference® (AAIC) in Chicago.   July 30-August 1, we’ll be in Boston for the Neuropsychiatric Drug Development Summit (NDD).   We look forward to hearing from knowledgeable speakers and meeting with industry associates to discuss our capabilities and extensive experience with Alzheimer’s and other mental…

  Dr. Kathleen Anne Welsh-Bohmer, a leading scientific expert in Alzheimer’s Disease (AD) research, has joined NeuroCog Trials (NCT) as the Vice President of Neurodegenerative Disorders. Dr. Welsh-Bohmer will lead the ongoing development of new technology and tools such as wearables and custom in-house assessments, designed to support customers conducting clinical trials for dementia and…

Alkermes plc today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides…

The Alliance sites take placebo response within our clinical trials quite seriously – we often lament that it is one constant that keeps our investigators up at night. As such, we engage in a multitude of activities and interventions to manage the placebo effect. For example, one of our research sites, Hassman Research Institute (HRI),…

Site Recognition Award commemorates exceptional performance of Collaborative Neuroscience Network.

Hassman Research Institute (HRI) proudly announced that Elan Cohen, Ph.D. has recently earned his Psychology license in New Jersey, and as such, can fulfill the role of Principal Investigator (PI) for numerous clinical trials focused on central nervous system (CNS) and related indications. Although Dr. Cohen has been licensed as a Psychologist for over 10…

At the American Psychiatric Associations’ annual meeting in New York City, David Walling, Ph.D., CEO and Principal Investigator for Collaborative Neuroscience Network, sat down with MD Magazine to talk about the biggest misconceptions about patients with schizophrenia—including the high rate of suicide among this patient population—and what’s being done to address them. He also spoke…